Zoetis Stock Testing Price Floor – Buy Now?
Zoetis (ZTS) stock should be on your watchlist. Here is why – it is currently trading in the support zone ($75.51 – $83.45), levels from which it has bounced meaningfully before. Since it first started trading, Zoetis stock received buying interest at this level 3 times and subsequently went on to generate 69.8% in average peak returns.
| Peak Return | Days to Peak Return | |
|---|---|---|
| 2/23/2018 | 15.4% | 259 |
| 12/21/2018 | 7.4% | 47 |
| 2/6/2019 | 186.5% | 1057 |
Yet, a support zone alone isn’t enough; rebounds are more likely when fundamentals, sentiment, and market conditions line up. How does that look for ZTS?
Rebound likely amidst valuation support and pipeline.
Zoetis plunged post-Q1 misses and cut guidance, reflecting intensified competition and pet owner price sensitivity in U.S. companion animal. However, the stock’s current 13.31x TTM P/E suggests undervaluation versus its 5-year median of 35.67x. Analyst median targets still indicate substantial upside from current levels. Insider buying and the growing animal health market, driven by pet humanization and technological advancements, provide foundational support. Long-term rebound hinges on effective new product pipeline execution against competitive pressures.
- Is Salesforce Stock Deeply Undervalued At $175?
- Earn 11% Today or Buy DAL 30% Cheaper – It’s a Win-Win
- BSX Stock: Don’t Try To Catch The Falling Knife
- Cash Machine Trading Cheap – BlackLine Stock Set to Run?
- Five-Year Tally: Altria Stock Delivers $43 Bil Gain
- Years of Rewards: $43 Bil From Qualcomm Stock
How Do ZTS Financials Look Right Now?
- Revenue Growth: 2.6% LTM and 5.5% last 3-year average.
- Cash Generation: Nearly 23.5% free cash flow margin and 37.6% operating margin LTM.
- Recent Revenue Shocks: The minimum annual revenue growth in the last 3 years for ZTS was 2.6%.
- Valuation: ZTS stock trades at a PE multiple of 12.7
| ZTS | S&P Median | |
|---|---|---|
| Sector | Health Care | – |
| Industry | Pharmaceuticals | – |
| PE Ratio | 12.7 | 23.9 |
|
|
||
| LTM* Revenue Growth | 2.6% | 7.4% |
| 3Y Average Annual Revenue Growth | 5.5% | 5.7% |
| Min Annual Revenue Growth Last 3Y | 2.6% | 0.6% |
|
|
||
| LTM* Operating Margin | 37.6% | 18.4% |
| 3Y Average Operating Margin | 36.8% | 18.3% |
| LTM* Free Cash Flow Margin | 23.5% | 14.4% |
*LTM: Last Twelve Months | For more details on ZTS fundamentals, read Buy or Sell ZTS Stock.
And What If The Support Breaks?
ZTS isn’t immune to market sell-offs. It fell 17% in the 2018 correction, 36% during the Covid pandemic, and nearly 47% in the inflation shock. Despite its strengths, these dips show the stock can still take a big hit when the market turns. Solid fundamentals help, but risk remains when volatility spikes.
But the risk is not limited to major market crashes. Stocks fall even when markets are in good shape – think events like earnings, business updates, outlook changes. Read ZTS Dip Buyer Analyses to see how the stock has recovered from sharp dips in the past.
Still not sure about ZTS stock? Consider the portfolio approach.
Portfolios Win When Stock Picks Fall Short
Single stocks swing wildly, but staying invested matters. A well-built portfolio helps you stay invested, captures upside, and softens the blows from individual stocks.
The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? HQ Portfolio has posted more than 105% in cumulative return since inception, with less risk versus the benchmark index, as evident in HQ Portfolio performance metrics.